Streetbeat News

Regulatory

CTHR

Charles & Colvard has received a letter from the Nasdaq Listing Qualifications Department regarding non-compliance with listing requirements.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 8:46 pm

RIGL

Rigel Pharmaceuticals has issued a Dear Healthcare Provider letter for GAVRETO after consulting with the FDA about a new safety signal. GAVRETO is used for treating certain types of cancer, including RET fusion-positive non-small cell lung cancer and thyroid cancer.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 8:42 pm

MDT

Medtronic has received FDA approval for its Affera Mapping and Ablation System, which includes the Sphere-9 catheter. This is the first all-in-one high-definition mapping and dual energy ablation device designed for treating atrial fibrillation and atrial flutter.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 8:36 pm

AERT

Aeries Technology has regained compliance with Nasdaq listing standards after filing its Form 10-Q and Form 10-K, resolving previous compliance issues.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 8:21 pm

KUKE

Kuke Music has received non-compliance notices from the NYSE due to its market capitalization and average closing price falling below required standards. The company's 30-day average market cap is $47 million, and its ADSs average closing price is $0.98, below the $1 minimum.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 8:14 pm

ARDX

Ardelyx, Inc. presented additional data on XPHOZAH at the American Society of Nephrology's Kidney Week, highlighting its effectiveness in managing hyperphosphatemia in CKD patients on dialysis. XPHOZAH is a first-in-class phosphate absorption inhibitor approved by the FDA.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 8:13 pm

JFBR

Jeffs' Brands shares rose after the company received a 180-day extension to regain Nasdaq compliance.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 8:04 pm

JFBR

Jeffs' Brands has been granted a 180-day extension by Nasdaq to regain compliance with the $1 minimum bid price requirement. There is no immediate impact on its listing status.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 8:03 pm

GSK

PFE

GSK has released promising preliminary data for its RSV vaccine, Arexvy, showing potential for use in adults aged 18-49 at increased risk for lower respiratory tract disease. This comes after Pfizer's RSV vaccine approval for younger adults. GSK's vaccine is currently approved for older adults, and the new data could expand its use to a broader population.

Portfolio Pulse from Vandana Singh

October 24, 2024 | 8:02 pm

LDOS

Leidos has received a success memorandum from the Defense Innovation Unit for its Electric Vehicle Charging as a Service prototype for the Department of the Air Force, establishing it as the sole vendor for a FedRAMP-accredited solution for the Department of Defense.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 8:02 pm